Document is current
Any future updates will be listed below
-
Authors
Risbjerg, Rasmus Strøm
Hansen, Mie Vennize
Sørensen, Anne Sofie
Kragstrup, Tue Wenzel https://orcid.org/0000-0002-6439-397X
-
Funding
Funding for this research was provided by:
Sundhed og Sygdom, Det Frie Forskningsråd (9039-00015B)
- License Information
-
More Information
Article History
Received: 26 March 2020
Accepted: 19 May 2020
First Online: 25 May 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: TWK has engaged in educational activities talking about immunology in rheumatic diseases receiving speaking fees from Pfizer, speaking fees from Bristol-Myers Squibb, speaking fees from Eli Lilly, speaking fees from Novartis, and speaking fees from UCB and has received a consultancy fee from Bristol-Myers Squibb. TWK is co-owner and clinical developer at the start-up company iBIO TECH ApS developing diagnostics and medicines for the treatment of immune mediated inflammatory disease. These engagements do not cause direct conflicts of interest concerning this study. The rest of the authors declare no potential conflicts of interest relevant to this article.
